Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference

Rhea-AI Summary

Kaleido Biosciences (Nasdaq: KLDO) will have CEO Dan Menichella present at the JMP Securities Life Sciences Conference on June 17, 2021, at 4 PM ET. This event will focus on Kaleido's innovative approach to microbiome-targeted therapies for disease treatment. Investors can access the live webcast through Kaleido’s website, with an archived replay available for 90 days post-event. The company aims to transform healthcare through its proprietary Microbiome Metabolic Therapies (MMT™), addressing significant unmet patient needs.

LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will deliver a corporate presentation at the JMP Securities Life Sciences Conference at 4PM ET on Thursday, June 17.

The webcast of the presentation will be made available in the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 90 days following the event.

About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.

Contacts:

Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com

Investors
Mike Biega
Solebury Trout
617-221-9660
mbiega@soleburytrout.com

Media
Amy Bonanno
Solebury Trout
914-450-0349
abonanno@soleburytrout.com

FAQ

When will Kaleido Biosciences present at the JMP Securities Life Sciences Conference?

Kaleido Biosciences will present at the JMP Securities Life Sciences Conference on June 17, 2021, at 4 PM ET.

Where can I watch the Kaleido Biosciences presentation?

The presentation can be watched live on Kaleido’s website in the Investors & Media section.

What is the purpose of Kaleido Biosciences' presentation at the conference?

The presentation aims to discuss Kaleido's innovative microbiome-targeted therapies and advancements in healthcare.

How long will the replay of Kaleido's conference presentation be available?

An archived replay of the presentation will be available for 90 days after the event.

What are Microbiome Metabolic Therapies (MMT™)?

MMT™ are therapies developed by Kaleido to modulate the metabolic profile of the microbiome to treat various diseases.